Results 1 to 10 of about 5,515 (141)

Achieved targeted heart rate following ivabradine therapy correlates with left ventricular reverse remodeling in non-ischemic dilated cardiomyopathy [PDF]

Scientific Reports
The effect of ivabradine on left ventricular reverse remodeling (LVRR) in heart failure with reduced ejection fraction and its correlation with achieved heart rate (HR) by ivabradine in non-ischemic dilated cardiomyopathy (NIDCM) remain uncertain.
Jooyeon Lee, Jaewon Oh, Jaehyung Ha, Chan Joo Lee, Seok-Min Kang   +4 more
doaj   +2 more sources

Association between NT-proBNP and ivabradine in patients after noncardiac surgery: a per-protocol analysis of the PREVENT-MINS study [PDF]

Anaesthesiology Intensive Therapy
Background The PREVENT-MINS trial investigated whether perioperative heart rate reduction with ivabradine could prevent myocardial injury after noncardiac surgery (MINS). Although ivabradine modestly reduced heart rate, it did not reduce the incidence of
Jacek Gorka, Zbigniew Putowski, Anna Wludarczyk, Michal Jedrusiak, Szymon Bialka, Piotr Palaczynski, Michał Borys, Paweł Kutnik, Tomasz Czarnik, Anna Szczepanska, Stanisław Wawrzyniak, Marcin Mozanski, Milena Keska, Katarzyna Kotfis, Janusz Trzebicki, Jan Aszkielaniec, Joanna Solek-Pastuszka, Pawel Grudzien, Wojciech Mudyna, Mateusz Kreczko, Zhiguo Zhao, P.J. Devereaux, Wojciech Szczeklik   +22 more
doaj   +2 more sources

Ivabradine

Reactions Weekly
Reed M, Patel P.
europepmc   +5 more sources

The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study

Heart Views, 2021
Background: Ivabradine is recommended in heart failure (HF) patients to reduce cardiovascular death and hospitalization due to worsening of HF symptoms.
Sara Al-Balushi, Mohammed Fasihul Alam, Abdul Rehman Abid, Amal Sharfi   +3 more
doaj   +1 more source

Ivabradine

Reactions Weekly, 2015
Heart failure affects over 5 million people in the United States and carries a high rate of mortality. Ivabradine, a new agent has been added to the current medical options for managing heart failure. It is a selective funny current ( If) inhibitor in sinoatrial node and slows its firing rate, prolonging diastolic depolarization without a negative ...
Rahul, Chaudhary, Jalaj, Garg, Parasuram, Krishnamoorthy, Neeraj, Shah, Gregg, Lanier, Mathew W, Martinez, Ronald, Freudenberger   +6 more
  +7 more sources

Early administration of ivabradine in patients admitted for acute decompensated heart failure

Frontiers in Cardiovascular Medicine, 2022
BackgroundHeart rate (HR) control is important in heart failure (HF) patients with reduced ejection fraction, and ivabradine is indicated for patients with chronic HF and sinus rhythm.
Teng-Yao Yang, Meng-shu Tsai, Jeng-Yu Jan, Jung-Jung Chang, Chang-Ming Chung, Ming-Shyan Lin, Hui-Ming Chen, Yu-Sheng Lin   +7 more
doaj   +1 more source

Ivabradine toxicity: a case report

Journal of Medical Case Reports, 2022
Background We describe a case of symptomatic bradycardia resulting from ivabradine toxicity by measurement of ivabradine levels, of which there are limited reports in the literature.
Kavisha Singh, Muthukumar R. Alagarraju, Carl E. Wolf, Justin L. Poklis, Nitin Kulkarni, William Tharpe, Parag H. Joshi   +6 more
doaj   +1 more source

Case report: Ivabradine induced Torsades de Pointes

IHJ Cardiovascular Case Reports, 2023
Ivabradine is used to control heart rate in patients of heart failure with reduced ejection fraction. Although considered safe, it is reported to prolong QTc interval when given with other QTc prolonging drugs or in setting of hypokalemia or ...
Mohit M. Bhagwati, K.K. Talwar, Amitabh Yaduvanshi   +2 more
doaj   +1 more source

Observational study of new-onset atrial fibrillation in patients treated with Ivabradine alone versus Ivabradine and β-blocker drug (The BetaBrad Study)

MGM Journal of Medical Sciences, 2022
Introduction: Ivabradine is a heart rate lowering agent by inhibiting Iƒ current in sinus node. It is approved for use in patients with angina and heart failure for heart rate control.
Rohan S Thanedar, Srinivas Kudva, Prakash Sanzgiri, Charan Reddy   +3 more
doaj   +1 more source

Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation

ESC Heart Failure, 2022
Aims Ivabradine is indicated for heart failure (HF) patients with reduced ejection fraction (HFrEF), but limited data are available with regards to the use of ivabradine in those with a history of paroxysmal atrial fibrillation (AF). To assess the effect
Yu‐Sheng Lin, Jeng‐Yu Jan, Jung‐Jung Chang, Ming‐Shyan Lin, Teng‐Yao Yang, Po‐Chang Wang, Mien‐Cheng Chen   +6 more
doaj   +1 more source